PT-141 (Bremelanotide)

PT-141 (Bremelanotide) is a synthetic peptide analogue of $\alpha$-melanocyte-stimulating hormone ($\alpha$-MSH). Specifically, it acts as a selective agonist across central melanocortin receptors, displaying high affinity for the MC3R and MC4R subtypes within the central nervous system.

Mechanistically, research has focused on its targeted receptor-binding kinetics and downstream neural signaling cascades within the hypothalamus. In contrast to conventional compounds that act directly on peripheral vascular pathways, PT-141 initiates its physiological effects at the level of the brain.

Consequently, studies have evaluated distinct receptor selectivity profiles and neurochemical outcomes across various research models. In addition, researchers have explored its functional interaction with mesolimbic dopaminergic pathways, given the established links between central melanocortin signaling and neural reward or motivation circuits. Furthermore, this centrally mediated action distinguishes PT-141 from peripherally active vasoactive agents by triggering downstream autonomic pathways rather than directly relaxing smooth muscle. Overall, as a centrally acting compound with a unique pharmacological target, PT-141 remains a prominent model in neuroendocrine and receptor biology research.